Race/ethnicity and the perception of the risk of developing prostate cancer
- PMID: 19423272
- PMCID: PMC3347707
- DOI: 10.1016/j.amepre.2009.03.007
Race/ethnicity and the perception of the risk of developing prostate cancer
Abstract
Background: Although the higher risk of prostate cancer for African-American men is well known in the medical community, it is not clear how prevalent this knowledge is among African-American men themselves. Both the side effects of treatment and the lack of a demonstrated mortality benefit of routine screening with the prostate-specific antigen test among men in the general population have increased the focus on patient participation in decision making about prostate cancer screening.
Methods: Data on 1075 male respondents to the 2003 Health Information National Trends Study were collected from October 2002 to April 2003 and analyzed in 2008 to examine the associations among race/ethnicity, demographic characteristics, and the perception of the risk of developing prostate cancer for African-American, Hispanic, and non-Hispanic white men aged >or=45 years without a history of prostate cancer.
Results: Nearly 50% of African-American men, 47.4% of Hispanic men, and 43.3% of non-Hispanic white men perceived their likelihood of getting prostate cancer as somewhat or very low. Nearly 18% of African-American men, 21.6% of Hispanic men, and 12.9% of non-Hispanic white men perceived themselves to be more likely to get prostate cancer than the average man of the same age.
Conclusions: Despite statistics to the contrary, few African-American men perceived themselves to have a higher-than-average risk of prostate cancer, while a higher percentage of Hispanic men perceived their risk to be higher than that of the average man of the same age. These findings suggest that all men, but particularly African-American and Hispanic men, could benefit from information regarding their specific risk of developing prostate cancer before making a decision about prostate cancer screening.
Similar articles
-
Race/ethnicity, risk perception, and receipt of prostate-specific antigen testing.J Natl Med Assoc. 2009 Jul;101(7):698-704. doi: 10.1016/s0027-9684(15)30979-2. J Natl Med Assoc. 2009. PMID: 19634591
-
Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.Med Care. 2004 Mar;42(3):239-50. doi: 10.1097/01.mlr.0000117361.61444.71. Med Care. 2004. PMID: 15076823
-
Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.J Natl Cancer Inst. 2001 Mar 7;93(5):388-95. doi: 10.1093/jnci/93.5.388. J Natl Cancer Inst. 2001. PMID: 11238701
-
Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.J S C Med Assoc. 2006 Aug;102(7):241-9. J S C Med Assoc. 2006. PMID: 17319238 Review.
-
Black men are dying from prostate cancer.ABNF J. 2008 Summer;19(3):92-5. ABNF J. 2008. PMID: 18717207 Review.
Cited by
-
How a population-based cohort of men estimate lifetime risk of prostate cancer in a survey before entering a prostate cancer screening trial in Sweden?BMJ Open. 2024 Aug 17;14(8):e083562. doi: 10.1136/bmjopen-2023-083562. BMJ Open. 2024. PMID: 39153780 Free PMC article.
-
Accuracy of prostate cancer screening recommendations for high-risk populations on YouTube and TikTok.BJUI Compass. 2022 Nov 8;4(2):206-213. doi: 10.1002/bco2.200. eCollection 2023 Mar. BJUI Compass. 2022. PMID: 36816146 Free PMC article.
-
Relationship between mental health disorder symptoms and negative cancer perceptions among U.S. adults.Cancer Causes Control. 2023 Apr;34(4):295-305. doi: 10.1007/s10552-022-01665-9. Epub 2023 Jan 2. Cancer Causes Control. 2023. PMID: 36593424
-
Predictors of prostate cancer screening among African American men treated at an Academic Medical Center in the Southern United States.Curr Cancer Rep. 2021 Jun 15;3(1):81-94. doi: 10.25082/CCR.2021.01.003. Epub 2021 Apr 2. Curr Cancer Rep. 2021. PMID: 33898998 Free PMC article.
-
Flaxseed Lignans as Important Dietary Polyphenols for Cancer Prevention and Treatment: Chemistry, Pharmacokinetics, and Molecular Targets.Pharmaceuticals (Basel). 2019 May 5;12(2):68. doi: 10.3390/ph12020068. Pharmaceuticals (Basel). 2019. PMID: 31060335 Free PMC article. Review.
References
-
- National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) Program DevCan database: SEER 17 incidence and mortality, 2000–2003, with Kaposi’s sarcoma and mesothelioma. seer.cancer.gov/csr/1975_2003/results_merged/sect_23_prostate.pdf. Released April 2006, based on the November 2005 submission. Underlying mortality data provided by NCHS ( www.cdc.gov/nchs)
-
- Myers RE, Wolf TA, Balshem AM, Ross EA, Chodak GW. Receptivity of African-American men to prostate cancer screening. Urology. 1994;43:480–487. - PubMed
-
- American Cancer Society. Atlanta GA: American Cancer Society; 2007. American Cancer Society guidelines for the early detection of cancer.
-
- American Urological Association Foundation. Prostate cancer screening. www.urologyhealth.org/adult/index.cfm?cat_09&topic_250.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
